Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Immunotherapy

Tumour Site

Presenters

Yuping Sun

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

Y. Sun1, T. Yi2, Q. Dang1, Y. Zhang1, S. Ni1, A. wu3, X. Zhao4, Z. Wang3, Q. Lu3, W. Tian3

Author affiliations

  • 1 Phase I Drug Clinical Trial Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NA - Jinan/CN
  • 2 Oncology Department, Xiangyang central hospital hubei university of art and science, 441000 - Xiangyang/CN
  • 3 Clincal Department, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., 200000 - Shanghai/CN
  • 4 Clincal Department, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., 201203 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 662P

Background

IMM2520 consists of a PD-L1 antibody with an engineered ADCC-enhanced IgG1 Fc region, linked to the domain of SIRPα at the N-terminus of heavy chains. Blockade of PD-L1 and CD47- SIRPα pathway fully activate macrophages and induce enhanced ADCP and ADCC activity, leading to potent integrated antitumor response.

Methods

This is an open-label, first in human, dose escalation and dose expansion phase1 study to evaluate the safety, RP2D/MTD and anti-tumor effect for IMM2520 in pts with advanced solid tumor. The dose escalation was designed with an accelerated titration at first dose level followed by standard 3+3 design. IMM2520 was administered weekly in a 28 day-cycle. Additional patients will be enrolled for potential RP2D to identify optimized dose level. Here we report results in ongoing dose escalation stage.

Results

As of 4 Apr 2024, 18 patients (pts) were treated at 5 dose levels (from 0.1mpk to 4mpk). Most pts (61%) previously received ≥ 3 lines of systemic anti-tumor therapy, including 9 (50%) pts with PD-(L)1 therapy history. No DLTs were observed yet. All pts reported treatment-related adverse event (TRAE), of which 10 (56%) pts were ≥ Grade 3. The most common TRAE of any grade was platelet decreased (89%), anemia (67%), white blood cell decreased (56%) and infusion-related reaction (IRR) (56%). The most common TRAE of ≥ Grade 3 was lymphocyte decreased (50%), platelet decreased (33%) and anorexia (5.6%). No AE leading to treatment discontinuation was observed. Of 11 efficacy evaluable pts,1 unconfirmed partial response (PR) in small cell lung cancer (SCLC) at 2mpk (with 2 previous lines of therapy including immunotherapy and negative PD-L1 expression) and 5 stable disease (SD) were observed, including 1 cervical cancer with 21.1% tumor shrinkage and 1 colorectal cancer with 11.1% tumor shrinkage. Pharmacodynamic biomarker included CD47 Target occupancy (TO) on peripheral circulating CD3+T cells using flow cytometry analysis. The rate of CD47 TO was mild and exhibits a dose-dependent trend.

Conclusions

IMM2520 showed tolerance at the evaluated doses and preliminary anti-tumor activity in advanced solid tumor, especially for SCLC. The dose escalation is ongoing.

Clinical trial identification

NCT05780307.

Editorial acknowledgement

Legal entity responsible for the study

ImmuneOnco BioPharmaceuticals (Shanghai) Inc.

Funding

ImmuneOnco BioPharmaceuticals (Shanghai) Inc.

Disclosure

A. Wu, X. Zhao, Z. Wang, Q. Lu: Financial Interests, Personal, Full or part-time Employment: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. W. Tian: Financial Interests, Personal, Stocks or ownership: ImmuneOnco BioPharmaceuticals (Shanghai) Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.